Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Intermediate-risk non-muscle-invasive bladder cancer is defined by recurrences, and many patients undergo repeated procedures as their tumors return

  60% confidence

• The high and durable complete responses demonstrated with Erda-iDRS highlight the opportunity to deliver a targeted therapy to these patients

  60% confidence

• FGFR alterations are common in early-stage bladder cancer, occurring in approximately 70 percent of intermediate-risk and 40 percent of high-risk non-muscle-invasive bladder cancer tumors

  60% confidence

• Bringing a biology-based approach into earlier stages of bladder cancer has the potential to change how these patients are treated

  60% confidence

• Erda-iDRS is designed to provide prolonged release of erdafitinib directly into the bladder over a three-month period, enabling localized treatment while minimizing systemic exposure and risk of adverse events

  60% confidence

• Treatment with Erda-iDRS led most patients with FGFR-altered disease to achieve a complete response by the end of the second treatment cycle, and many of those responses were sustained over time

  60% confidence

• For patients with FGFR-altered non-muscle-invasive bladder cancer, care has historically not been guided by precision-based approaches

  60% confidence

• Achieving and maintaining a complete response is particularly meaningful in intermediate-risk NMIBC setting where recurrence is common and requires repeated surgical intervention

  60% confidence

• Erda-iDRS has the potential to be the first targeted treatment for early-stage bladder cancer

  60% confidence